D'Agostino R B, Kannel W B, Stepanians M N, D'Agostino L C
Mathematics Department, College of Liberal Arts, Boston University, Massachusetts.
Clin Ther. 1992 May-Jun;14(3):390-5.
In a previous report of a multicenter study (Kannel et al, 1990), the results of 6 months' treatment with lovastatin in 489 adults with primary hypercholesterolemia were presented. The present report contains the results from the 236 women patients. The intial dose of lovastatin was 20 mg daily and could be increased to a maximum of 80 mg/day. At the end of 1 month of treatment, levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, very-low-density lipoprotein cholesterol, triglycerides, and the total cholesterol:high-density lipoprotein (HDL) cholesterol and LDL:HDL cholesterol ratios were significantly lower and the HDL cholesterol levels were significantly higher. These improvements in the lipid profile were maintained for 6 months. The results in the 88 women aged 65 to 83 years and in the 147 women aged 25 to 64 years were similar. LDL-cholesterol goals of less than 3.36 mmol/L in patients with coronary heart disease (CHD) or two or more CHD risk factors and less than 4.14 mmol/L among the other patients were achieved by 48% of the women at 1 month and 58% by 6 months. At least one adverse effect was reported by 18% of the women, the most common being abdominal pain, diarrhea, and constipation. The results indicate that hypercholesterolemic women respond well to treatment with lovastatin.
在之前一项多中心研究的报告中（坎内尔等人，1990年），呈现了489名原发性高胆固醇血症成年患者接受洛伐他汀6个月治疗的结果。本报告包含236名女性患者的结果。洛伐他汀的初始剂量为每日20毫克，最大可增至每日80毫克。治疗1个月结束时，总胆固醇、低密度脂蛋白（LDL）胆固醇、极低密度脂蛋白胆固醇、甘油三酯水平，以及总胆固醇与高密度脂蛋白（HDL）胆固醇之比和LDL与HDL胆固醇之比均显著降低，而HDL胆固醇水平显著升高。这些血脂指标的改善持续了6个月。88名年龄在65至83岁的女性和147名年龄在25至64岁的女性的结果相似。冠心病（CHD）患者或有两个或更多CHD危险因素的患者，LDL胆固醇目标低于3.36毫摩尔/升，其他患者低于4.14毫摩尔/升，1个月时48%的女性达到目标，6个月时58%达到目标。18%的女性报告了至少一种不良反应，最常见的是腹痛、腹泻和便秘。结果表明，高胆固醇血症女性对洛伐他汀治疗反应良好。
